United Therapeutics (UTHR) has put a fresh US$2.0b share repurchase program on the table, running through October 2027. This move directly affects how current and future shareholders think about each remaining share.
United Therapeutics has recently paired this US$2.0b buyback authorization with a strong run in its shares, with a 30-day share price return of 17.52% contributing to a 37.21% total shareholder return over the past year and a 204.31% total shareholder return over five years.
Scan other potential buyback and value plays with the curated 29 high quality undervalued stocks that combine stronger balance sheets with more measured pricing than United Therapeutics right now.
United Therapeutics looks like a powerful rare-disease and xenotransplantation story, now paired with a fresh US$2.0b buyback. The real issue is whether that strength is already fully reflected in today’s share price.
Most Popular Narrative: 10% Undervalued
United Therapeutics is framed as undervalued in the most widely followed narrative, with a fair value of $651.15 versus a last close of $584.79. This perspective puts the buyback and clinical pipeline into a different light for anyone focused on the medium term.
The main factor that has to go right is broad and durable adoption of nebulized Tyvaso and ralinepag across pulmonary fibrosis and PAH, supported by regulatory approvals, commercial execution, and effective management of tolerability and dosing concerns.
See why 34 investors see United Therapeutics as 10% undervalued.
Result: Fair Value of $651.15 (UNDERVALUED)
Still, the United Therapeutics story depends heavily on successful Tyvaso use in tougher pulmonary fibrosis settings, as well as on organ programs moving from trials to meaningful commercial scale.
Find out about the key risks to this United Therapeutics narrative.
Another View: What Multiples Say About United Therapeutics
United Therapeutics screens as cheap against the SWS fair ratio, with a P/E of 19.1x versus a fair ratio of 26x, even though it trades a little richer than the US Biotechs industry at 18.4x and below a 24.8x peer average. That mix of discount and slight premium raises a simple question for investors. Is the market underestimating the durability of this earnings profile or rightly applying a safety margin to a complex rare-disease and organ platform story?
For a closer look at how this valuation gap could close or widen over time, and what the earnings math implies for risk, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Plenty in this United Therapeutics story points to optimism, so move quickly to test the numbers, pressure test the narratives, and weigh the upside against the risks. Then see what stands out in the 3 key rewards
Looking for more United Therapeutics investment ideas?
If you stop with United Therapeutics, you risk missing other opportunities that match your style, your risk tolerance, and your return goals.
- Hunt for quality at a discount by scanning companies on the 29 high quality undervalued stocks that pair stronger fundamentals with pricing that still looks restrained.
- Prioritize resilience and sleep-better-at-night holdings by focusing on businesses in the 30 resilient stocks with low risk scores that our models flag with more durable profiles.
- Target sturdier foundations by filtering for companies in the list of solid balance sheet and fundamentals (26 results) that combine healthier balance sheets with fundamentals that can support long-term plans.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com